Skip to main content
HairCited

ミノキシジル 女性型脱毛症

A

合計28,815名の参加者を対象とした67件の研究(メタアナリシス4件、RCT 11件を含む)に基づく。67件中53件の研究で肯定的な効果が示されている。

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dminoxidil\u0026condition\u003Dfemale\u002Dpattern\u002Dhair\u002Dloss'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

結論

Research strongly suggests that minoxidil may help women with female pattern hair loss regain hair density, supported by numerous high-quality clinical trials.

  • 67 studies including 11 RCTs and 4 meta-analyses specifically in women
  • 79% of studies report positive effects on hair growth
  • Low-dose oral minoxidil is emerging as a well-tolerated alternative to topical application
  • Combination with other ingredients like spironolactone may enhance results

Key Study Findings

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None 効果: None None

対象集団: women with androgenetic alopecia (female pattern hair loss)

Other
Low-dose oral minoxidil (LDOM) and topical minoxidil: consensus recommendations for managing male and female pattern …
Dose: MPHL: 1.25-2.5 mg/day; FPHL: 0.625-1.25 mg/day vs: None Outcome: consensus recommendations for managing pattern hair loss 効果: None None

対象集団: hair transplant patients with male and female pattern hair loss (Delphi panel consensus)

review
Antiandrogen therapy for the treatment of female pattern hair loss: A clinical review of current …
Dose: varies by agent and study vs: Placebo 効果: variable; oral antiandrogens demonstrate some efficacy; topical antiandrogens possibly fewer systemi None
narrative review
Addressing the Root Causes of Female Hair Loss and Non-Pharmaceutical Interventions.
Dose: None vs: Placebo 効果: None None
randomized controlled trial n=45 16 weeks Open-label
Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in …
Dose: Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi vs: Placebo 効果: Groups A and C showed significant improvement on Sinclair scale and trichoscopic hair density; Group None
Review
Male and female pattern hair loss.
Dose: None vs: Placebo 効果: None None

Key Statistics

111

研究数

37800

参加者数

Positive

A

グレード

Referenced Papers

Australian prescriber 2025 2 件の引用
Annals of dermatology 2025
SAGE open medical … 2024 3 件の引用
Drugs 2023 221 件の引用
Anais brasileiros de … 2023 29 件の引用
Journal of cosmetic … 2023 3 件の引用
The Journal of … 2022 170 件の引用
Faculty reviews 2022 44 件の引用
Journal of cosmetic … 2022 7 件の引用
Journal of the … 2021 42 件の引用
American journal of … 2020 127 件の引用
International journal of … 2020 58 件の引用
Indian dermatology online … 2020 31 件の引用
Actas dermo-sifiliograficas 2019 5 件の引用
International journal of … 2018 129 件の引用
Australian journal of … 2018 8 件の引用
JAMA dermatology 2017 121 件の引用
The Cochrane database … 2016 18 件の引用
The Medical clinics … 2015 66 件の引用
World journal of … 2015 62 件の引用
Seminars in cutaneous … 2015 27 件の引用
Seminars in cutaneous … 2015 20 件の引用
Clinical obstetrics and … 2015 9 件の引用
Current problems in … 2015 8 件の引用
Skin therapy letter 2014 29 件の引用
Journal of drugs … 2014 26 件の引用
Dermatologic clinics 2013 78 件の引用
International journal of … 2013 61 件の引用
Indian journal of … 2013 16 件の引用
International journal of … 2013
The Cochrane database … 2012 15 件の引用
Skinmed 2012 5 件の引用
The Australasian journal … 2011 44 件の引用
Seminars in cutaneous … 2009 4 件の引用
American family physician 2009
Journal of the … 2008 290 件の引用
The Australasian journal … 2007 32 件の引用
Clinical interventions in … 2007
Duodecim; laaketieteellinen aikakauskirja 2006
Journal of the … 2005 247 件の引用
The British journal … 2005 205 件の引用
The journal of … 2003 102 件の引用
Clinical and experimental … 2002 61 件の引用
Therapeutische Umschau. Revue … 2002 4 件の引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

topical:
2-5% solution, twice daily

上限量: 5% topical solution

研究で検討された用量

用量 期間 効果 N
None -- Neutral --
MPHL: 1.25-2.5 mg/day; FPHL: 0.625-1.25 mg/day -- Positive --
varies by agent and study -- Positive --
None -- Positive --
Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi 16 weeks Positive 45
None -- Positive --
Spironolactone 100 mg once daily 24 weeks Positive 48
None -- Positive --

推奨摂取タイミング: Apply to dry scalp morning and evening, at least 4 hours before bed

Safety & Side Effects

報告されている副作用

  • Scalp irritation and dryness
  • Initial shedding phase (first 2-8 weeks)
  • Unwanted facial hair growth (especially in women)
  • Dizziness or lightheadedness (rare with topical use)
  • Heart palpitations (rare, more common with oral form)

既知の相互作用

  • Antihypertensive medications (additive blood pressure lowering)
  • Topical corticosteroids (may increase absorption)
  • Retinoids (tretinoin may enhance penetration and side effects)

耐容上限摂取量: 5% topical solution

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does ミノキシジル help with 女性型脱毛症?
Based on 111 studies with 37,800 participants, there is strong evidence from multiple clinical trials that ミノキシジル may support 女性型脱毛症 management. Our evidence grade is A (Strong Evidence).
How much ミノキシジル should I take for 女性型脱毛症?
Studies have used various dosages. A commonly studied range is 2-5% solution, twice daily. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of ミノキシジル?
Reported side effects may include Scalp irritation and dryness, Initial shedding phase (first 2-8 weeks), Unwanted facial hair growth (especially in women), Dizziness or lightheadedness (rare with topical use). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for ミノキシジル and 女性型脱毛症?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 111 peer-reviewed studies with 37,800 total participants. The overall direction of effect is positive.

Related Evidence

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。